Could your daily struggles be undiagnosed ADHD?

The Adult ADHD Self-Report Scale version 1.1 was developed by the World Health Organization in collaboration with researchers at Harvard Medical School and New York University. It was designed as a brief screening tool that primary care physicians could administer in under two minutes. The full instrument has 18 items across two parts. Part A, the 6-item screener used here, was found to be the most predictive subset for identifying adults who may have ADHD. It has been translated into dozens of languages and is used in clinical settings worldwide.

Sensitivity measures how well the screener catches true cases. A sensitivity of 68.7% means that among people who genuinely have ADHD, the screener correctly flags about 69 out of 100. The remaining 31 would score below the threshold despite having the condition. This is why a low score does not rule out ADHD. The specificity of 99.5% means that among people without ADHD, only 0.5% would be incorrectly flagged. If you score above the threshold, the chance of a false alarm is very low. The screener misses some true cases but rarely raises false alarms.

No. This is a screening tool, not a diagnostic instrument. An ADHD diagnosis requires a comprehensive clinical assessment that typically includes a detailed developmental history, interviews with family members or partners, evaluation of other possible explanations for symptoms such as anxiety, depression, sleep disorders, or thyroid conditions, and often neuropsychological testing. The ASRS-v1.1 Part A is one small piece of that larger puzzle. If your score is above the threshold, it means a conversation with a healthcare professional is worthwhile, not that you have ADHD.

Research consistently shows that women with ADHD are diagnosed later and less frequently than men. The diagnostic criteria were historically developed from studies of hyperactive boys, so the predominantly inattentive presentation common in women was overlooked. Girls are socialised to develop stronger compensatory strategies, masking symptoms. Clinicians may attribute symptoms to anxiety or depression rather than investigating ADHD as the root cause. Many women reach their 30s or 40s before receiving a diagnosis, often after their children are diagnosed first.

Book an appointment with your GP (UK) or primary care physician (US/AU). Bring your ASRS result and describe the specific daily challenges you experience. In the UK, your GP can refer you to an adult ADHD assessment service, though NHS wait times currently exceed 12 months in most areas. Private assessments through Right to Choose pathways may be faster. In the US, you can request a referral to a psychiatrist or psychologist who specialises in adult ADHD. While waiting for an assessment, you can begin implementing structure and coping strategies that benefit people with ADHD regardless of formal diagnosis.

The screener has a sensitivity of 68.7%, meaning it misses roughly one in three true cases. If your daily functioning is significantly impaired by inattention, disorganisation, restlessness, or impulsivity, a below-threshold score should not deter you from seeking professional evaluation. This is especially relevant for women and for people who have developed strong coping mechanisms that mask underlying difficulties. Consider completing the full 18-item ASRS (Part A and Part B combined) and bringing it to a clinician.

The full ASRS has 18 questions split into Part A (6 items) and Part B (12 items). Part A was statistically selected as the most discriminating subset for screening purposes. Part B provides additional clinical information but does not improve screening accuracy for the initial question of whether a person should be evaluated further. This calculator uses Part A because it strikes the best balance between brevity and predictive power. If you want a more detailed self-assessment before seeing a professional, completing Part B as well can give your clinician richer information to work with.

The ASRS-v1.1 was validated across adult age groups, but ADHD presentation does shift with age. Hyperactivity often decreases in adulthood, manifesting as internal restlessness rather than physical fidgeting. Inattention tends to persist or become more noticeable as life demands increase. The screener's questions are worded broadly enough to capture both younger and older presentations, but no brief screener perfectly accounts for these developmental shifts.

Stimulant medications, including methylphenidate and amphetamine-based formulations, are the first-line pharmacological treatment for ADHD in adults and have strong evidence of efficacy, with response rates around 70-80%. Non-stimulant options like atomoxetine are alternatives for people who cannot tolerate stimulants. However, medication is only one component of effective ADHD management. Cognitive behavioural therapy adapted for ADHD, coaching, environmental modifications, and lifestyle changes including exercise, sleep hygiene, and nutrition all contribute to better outcomes.

The evidence strongly suggests increased recognition rather than increased prevalence. Diagnostic criteria have broadened, awareness campaigns have reached mainstream audiences, and clinicians are better trained to spot ADHD in adults and in women. Population prevalence estimates have remained relatively stable at 2.8-4.4% across studies spanning two decades. What has changed dramatically is the proportion of those adults who actually receive a diagnosis and access treatment.